Systems pharmacology.
We examine how physiology and pathophysiology are studied from a systems perspective, using high-throughput experiments and computational analysis of regulatory networks. We describe the integration of these analyses with pharmacology, which leads to new understanding of drug action and enables drug discovery for complex diseases. Network studies of drug-target relationships can serve as an indication on the general trends in the approved drugs and the drug-discovery progress. There is a growing number of targeted therapies approved and in the pipeline, which meets a new set of problems with efficacy and adverse effects. The pitfalls of these mechanistically based drugs are described, along with how a systems view of drug action is increasingly important to uncover intricate signaling mechanisms that play an important part in drug action, resistance mechanisms, and off-target effects. Computational methodologies enable the classification of drugs according to their structures and to which proteins they bind. Recent studies have combined the structural analyses with analysis of regulatory networks to make predictions about the therapeutic effects of drugs for complex diseases and possible off-target effects.
Boran
Aislyn D W
AD
Mount Sinai School of Medicine, New York, NY, USA.
Iyengar
Ravi
R
D019295:Computational Biology; D015195:Drug Design; D006801:Humans; D009154:Mutation; D010597:Pharmacogenetics; D055553:Prescription Drugs; D015398:Signal Transduction; D049490:Systems Biology
D055553:Prescription Drugs